CRIS Current Research Information System

DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.405
NA - Nord America 3.433
EU - Europa 1.562
SA - Sud America 235
Continente sconosciuto - Info sul continente non disponibili 208
AF - Africa 156
OC - Oceania 10
Totale 10.009
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.284
VN - Vietnam 1.179
SG - Singapore 1.161
CN - Cina 871
HK - Hong Kong 512
IT - Italia 474
DE - Germania 326
BD - Bangladesh 244
BR - Brasile 160
KR - Corea 136
FR - Francia 128
NL - Olanda 123
SE - Svezia 123
GB - Regno Unito 91
FI - Finlandia 78
IN - India 77
CA - Canada 76
JP - Giappone 56
CI - Costa d'Avorio 46
IE - Irlanda 44
SC - Seychelles 40
RU - Federazione Russa 38
PH - Filippine 34
ID - Indonesia 31
AR - Argentina 22
PL - Polonia 22
TH - Thailandia 22
MX - Messico 21
TG - Togo 18
AT - Austria 17
BG - Bulgaria 17
BE - Belgio 16
CO - Colombia 15
EC - Ecuador 12
ES - Italia 12
GH - Ghana 12
VE - Venezuela 12
JM - Giamaica 11
TR - Turchia 11
TW - Taiwan 11
ZA - Sudafrica 11
AU - Australia 10
CH - Svizzera 10
CR - Costa Rica 10
IQ - Iraq 10
CL - Cile 8
JO - Giordania 8
GR - Grecia 7
UA - Ucraina 7
LT - Lituania 6
PK - Pakistan 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
HN - Honduras 5
CZ - Repubblica Ceca 4
GT - Guatemala 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
NP - Nepal 4
SA - Arabia Saudita 4
TN - Tunisia 4
AL - Albania 3
EE - Estonia 3
EG - Egitto 3
MD - Moldavia 3
PY - Paraguay 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
PT - Portogallo 2
SN - Senegal 2
SV - El Salvador 2
AO - Angola 1
BM - Bermuda 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
GP - Guadalupe 1
HT - Haiti 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LU - Lussemburgo 1
LY - Libia 1
MG - Madagascar 1
Totale 9.791
Salva come PNG Salva come JPEG
Città #
Singapore 872
San Jose 485
Hong Kong 458
Ashburn 377
Ho Chi Minh City 318
Hanoi 312
Hefei 299
Council Bluffs 207
Santa Clara 176
Los Angeles 174
Seoul 128
New York 97
Chandler 96
Beijing 92
Bologna 77
Boardman 74
Chicago 68
Buffalo 59
Da Nang 59
Lauterbourg 58
Dallas 55
Helsinki 53
Abidjan 46
Dublin 43
Haiphong 42
Krefeld 41
Rome 41
Tokyo 40
Milan 39
Princeton 39
Southend 37
Munich 33
Amsterdam 31
Frankfurt am Main 31
São Paulo 31
Bengaluru 27
Fairfield 27
Falkenstein 26
Shanghai 23
Lappeenranta 22
Jakarta 19
Lomé 18
Redondo Beach 18
Seattle 18
Houston 17
Nuremberg 17
Sofia 17
Guangzhou 16
Hải Dương 16
San Francisco 16
Toronto 16
Atlanta 15
Bad Bellingen 15
Shenzhen 14
Turin 14
Brooklyn 13
Brussels 13
Denver 13
Des Moines 13
Naples 13
Warsaw 13
Wilmington 12
Accra 11
Cambridge 11
London 11
Montreal 11
San Diego 11
Woodbridge 11
Bangkok 10
Berlin 10
Düsseldorf 10
Mexico City 10
Orem 10
Genoa 9
Kingston 9
Ninh Bình 9
Phoenix 9
Rio de Janeiro 9
Thái Nguyên 9
Tongling 9
Amman 8
Bắc Ninh 8
Can Tho 8
Charlotte 8
Fort Worth 8
San José 8
Biên Hòa 7
Bắc Giang 7
Florence 7
Ha Long 7
Hangzhou 7
Nha Trang 7
Simpsonville 7
Stockholm 7
Trento 7
Ann Arbor 6
Bexley 6
Bến Tre 6
Detroit 6
Hillsboro 6
Totale 5.869
Salva come PNG Salva come JPEG
Nome #
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 428
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 299
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 225
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 222
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 199
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 197
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 196
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 196
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 183
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 183
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 182
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 171
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 167
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 167
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 166
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome 166
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 161
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 159
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 156
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. 144
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 140
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 134
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 134
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 130
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 126
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 124
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 122
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 121
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 118
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 115
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 114
CAR-T cell therapy: A potential new strategy against prostate cancer 113
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 110
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 110
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 107
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 107
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 106
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 105
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 105
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 103
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 101
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 100
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 99
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 99
New prognostic biomarkers in metastatic castration-resistant prostate cancer 97
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 96
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 94
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial 94
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 94
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 94
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 92
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 92
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 91
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 91
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 91
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 86
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 84
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 84
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 83
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 82
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 82
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 82
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 79
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 76
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 75
Immunotherapy for prostate cancer: Where we are headed 75
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 74
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 69
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 69
Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3) 69
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 69
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 68
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 67
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 63
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA 63
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 63
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 63
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 62
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 62
Psychosocial issues in long-term survivors of testicular cancer 50
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 49
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 46
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 46
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 46
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 42
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 40
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 39
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 29
Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404](S1040842824001471)(10.1016/j.critrevonc.2024.104404) 27
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 26
Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors 23
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors 23
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 22
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 14
null 2
Totale 10.009
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.371
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.371
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022227 0 0 0 6 9 4 25 16 5 50 74 38
2022/2023343 20 48 11 47 22 44 8 16 72 9 20 26
2023/2024364 10 17 5 3 9 39 15 15 204 21 17 9
2024/20251.699 100 207 121 152 230 108 52 68 17 138 101 405
2025/20265.877 357 423 386 363 452 117 1.238 347 1.044 458 383 309
2026/20271.357 218 403 338 398 0 0 0 0 0 0 0 0
Totale 10.009